Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope discusses the future of isatuximab as an option in relapsed/refractory multiple myeloma.
